Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for viral infectious diseases, starting with COVID-19. Its core products include PEMGARDA for COVID-19 pre-exposure prophylaxis and VYD2311, a next-generation antibody candidate. The company leverages antibody discovery, engineering, and surveillance to create long-lasting, broadly neutralizing therapies, partnering with contract manufacturers and research organizations to support development, manufacturing, and commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.